- Home
- CHPT vs PRQR Comparison
CHPT vs PRQR Comparison
Compare CHPT & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHPT | PRQR |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.9M | 166.5M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CHPT | PRQR |
|---|---|---|
| Price | $5.68 | $1.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $9.25 | $7.25 |
| AVG Volume (30 Days) | ★ 683.4K | 564.8K |
| Earning Date | 06-03-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $411,224,000.00 | N/A |
| Revenue This Year | $4.18 | N/A |
| Revenue Next Year | $16.63 | $13.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.58 | $1.33 |
| 52 Week High | $12.62 | $3.10 |
Technical Indicators
Market Signals| Indicator | CHPT | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 37.54 | 59.22 |
| Support Level | $4.44 | $1.37 |
| Resistance Level | $7.00 | $2.07 |
| Average True Range (ATR) | 0.77 | 0.13 |
| MACD | -0.14 | 0.05 |
| Stochastic Oscillator | 0.00 | 65.83 |
Price Performance
Historical ComparisonAbout CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable charging systems owners, charge point operators, to manage their Networked Charging Systems, and to enable drivers to locate, reserve and authenticate Networked Charging Systems and to transact EV charging sessions on those systems. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. The company derives the majority of its revenue from the United States.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.